Kornimate/medical-research-clean huggingface dataset:
dysphagia management during covid-19 pandemic

Conditions: Dysphagia; Covid19

Summary: the current study is aimed to determine the procedures applied in the dysphagia clinics during the covid-19 pandemic period. a questionnaire consisting of 30 questions will be implemented. each participant will be asked to answer the questions.

the current study is aimed to understand the current clinical conditions and current practice regarding dysphagia management during the pandemic period/normalization period. it is a cross sectional online survey study. the first part is the survey development and testing, the second part is determination of swallowing centers and last part is survey distribution by google forms. a coordinator will be selected for each center to discuss the survey with the entire team and reply the questions.

Eligibility criteria:
inclusion criteria: * working on a dysphagia clinic from all over the world exclusion criteria: * not willing to participate * not working on a dysphagia clinic

Keywords: dysphagia covid-19
the effect of a pre-operative exercise program for patients with full thickness rotator cuff tear waiting for surgical repair

Conditions: Rotator Cuff Tears

Summary: this is a randomised controlled study involving a group of 20 patients- 10 patients in a control group, 10 patients in treatment group. the treatment group consists of exercises with theraband for the shoulder and exercises of motor control of the scapula. the purpose of the study is to measure the effects of a pre-operative physiotherapy program for patients awaitng for rotator cuff surgery, the duration of the pilot project is 4 weeks.

this study is taken place in a genral hospital using the waiting list in the orthopedic surgery department- only patients awaitng for rotator cuff surgery are included. a randomised process of a block will be used. there will be 2 groups of patients an active comparator and no intervention. all patients at the beginning of the project and after 4 weks will have an evaluation on range of motion, strength, acromial humeral mesurement done by ultrasound and questionnaire on pain(dash) and quality of life( worc). at 8 weeks all patients will fill in the 2 questionnaires on dash and worc.

Eligibility criteria:
inclusion criteria: * patients waitng for surgery at cite de la sante hospital exclusion criteria: * glenohumeral arthirtis * shoulder fracture * corticosteriod injections * rupture of rotator cuff tear of more than 3 cm * csst- workman's compensation * central and peripheral neuropathy

Keywords: rotator cuff tears ultrasound measure pain range of motion muscle force
safety study of the combination of tandutinib with temozolomide and bevacizumab after radiation and temozolomide in patients with newly diagnosed with glioblastoma multiforme

Conditions: Glioblastoma Multiforme

Summary: this is a safety study of tandutinib in combination with temozolomide and bevacizumab after people have received radiation therapy and temozolomide treatment. this study will determine the maximum safe dose of tandutinib when combined with temozolomide and bevacizumab and evaluate the safety of the combination treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of glioblastoma multiforme * received radiotherapy for glioblastoma multiforme * patients who have not had previous treatments for glioblastoma multiforme (except for surgery, radiation and temozolomide therapy) * females that are postmenopausal for at least 1 year prior to screening visit * 18 years of age and older exclusion criteria: * other brain cancers that are not diagnosed as glioblastoma multiforme * female patients who are lactating or are pregnant * hiv positive and/or any other active infection requiring therapy * known hepatitis b or hepatitis c infection * diagnosed or treated any other cancer within 2 years before the first dose * history of cardiovascular conditions and/or vascular disease * allergic to any component of bevacizumab
vibrotactile feedback in exoskeletons

Conditions: Spinal Cord Injuries

Summary: this study aims to investigate the impact of providing discrete vibrotactile feedback related to weight shift and step initiation on exoskeleton use in individuals with motor-complete sci.

rationale: people with motor-complete spinal cord injury (sci) lack motor function below the lesion level and are, thus, wheelchair-dependent. in recent years, wearable exoskeletons have emerged as potential mobility devices for this population. although exoskeletons generate the basic motions for ambulation, postural stability must be maintained by the user. people with motor-complete sci miss essential somatosensory perception, which affects their ability to maintain postural stability. hence, walking in an exoskeleton is demanding, and crutches are necessary. when sensory information of a specific system is lost, the lack of sensory information can be substituted by providing feedback to another sensory system. as sensory feedback has been shown to improve postural control in people missing essential sensory information, such sensory substitution may also be effectively incorporated in people with complete sci using an exoskeleton. objective: the study aims to investigate the effect of vibrotactile feedback on exoskeleton use in people with motor-complete sci. study design: the proposed study is an experimental study. the study protocol includes six sessions of 90 minutes spread over three weeks. sessions one to five are dedicated to training to assess the effect of vibrotactile feedback on exoskeleton motor learning. session six is dedicated to evaluation to assess the effect of vibrotactile feedback on exoskeleton motor control.

Eligibility criteria:
inclusion criteria: * sci classification american spinal injury association impairment scale (ais) a or b * minimally six months post-injury * prior experience with the rewalk exoskeleton, able to walk independently exclusion criteria: * pre-existing somatosensory problems before the sci * visual or auditory issues that are not resolved with glasses or a hearing device * insufficient mastery of the dutch language * contraindications related to the able exoskeleton

Keywords: exoskeletons sensory substitution vibrotactile feedback motor control motor learning
beta-lactoglobulin, immobilisation and muscle protein synthesis

Conditions: Muscle Atrophy

Summary: the objectives of this study are to: 1. establish whether combined β-lactoglobulin supplementation and resistance training for 1 week prior to 5 days of limb immobilisation will attenuate the decrease in integrated free-living rates of mps during short-term muscle disuse. 2. establish whether combined β-lactoglobulin supplementation and resistance training for 1 week prior to limb immobilisation will attenuate the decrease in muscle mass and strength during short-term muscle disuse.

the objectives of this study are to: 1. establish whether combined β-lactoglobulin supplementation and resistance training for 1 week prior to 5 days of limb immobilisation will attenuate the decrease in integrated free-living rates of mps during short-term muscle disuse. 2. establish whether combined β-lactoglobulin supplementation and resistance training for 1 week prior to limb immobilisation will attenuate the decrease in muscle mass and strength during short-term muscle disuse. hypotheses 1. combining β-lactoglobulin and resistance training for 1 wk prior to 5 d of limb immobilisation will attenuate the decrease in integrated muscle protein synthesis, muscle fibre csa, quadriceps muscle strength, and leg lean mass during muscle disuse. 2. combining β-lactoglobulin and resistance training for 1 wk prior to 5 d of limb immobilisation will attenuate the decrease in muscle fibre csa, quadriceps muscle strength, and leg lean mass during muscle disuse.

Eligibility criteria:
inclusion criteria: * male and female * aged 18-45 years * healthy * physically active (≥150-300 minutes of moderate-intensity aerobic physical activity per week or 75-150 minutes of vigorous-intensity aerobic physical activity per week) * eumenorrheic and not taking any hormonal birth control (females) exclusion criteria: * dairy allergy or intolerance * lower limb injury or surgery in the last 6 months, * lower limb osteoarthritis or other musculoskeletal disorder * a musculoskeletal or blood blotting disorder * an allergy to local anaesthetic * currently pregnant * current use of blood thinning medications * volunteers that take part in structured resistance exercise training * taking supplements considered to be anabolic to skeletal muscle (protein supplements, creatine, or omega-3 supplements) * consuming more than 1.2 grams of protein per kilogram of body mass per day in their habitual diet. * volunteers involved in other studies at the time of enrolment * volunteers who have taken part in a tracer study in the past 18 months * if without an understanding of verbal or written english * volunteers with a history of eating disorders
mind body program for vascular disease

Conditions: Peripheral Arterial Disease; Peripheral Vascular Diseases

Summary: the purpose of the current study is to conduct a proof-of-concept test regarding the delivery of a mind body program for vascular disease, focusing on support for depression, stress, and adherence, as part of patients' chronic disease management for peripheral artery disease (pad).


Eligibility criteria:
inclusion criteria: * rutherford score 1-4 (mild-severe claudication, or ischemic rest pain) * resting ankle-brachial index assessment ≤0.90 or drop in post-exercise ankle pressure ≥20 mmhg or non-compressible ankle-brachial index (≥1.30) or toe brachial index less than 0.70 in the past year * positive depression screening result (positive phq-9 result ≥10) or high stress screening result (10-item perceived stress scale score ≥27) exclusion criteria: * not speaking either english or spanish * age ≥18 years * currently incarcerated * current alcohol dependency or other substance use disorder (score ≥ 5 on nm-assist) * cognitive impairment (t-moca short \<10) * acute suicidal risk (positive screen asq tool) * history of psychosis or bipolar disorder * previously enrolled in the study * unable to provide written informed consent
phase ii study of rituximab in patients with immune thrombocytopenic purpura

Conditions: Purpura, Thrombocytopenic, Idiopathic

Summary: objectives: i. determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. ii. evaluate the toxicity associated with this treatment regimen in these patients. iii. evaluate the alteration in antiplatelet antibody with this treatment regimen in these patients.

protocol outline: patients receive rituximab iv on days 1, 8, 15, and 22. patients who achieve a clinical response lasting over 4 months may receive a second course of rituximab. patients are followed at 5, 6, 8, and 12 weeks, and then at 6 and 9 months.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- clinically confirmed immune thrombocytopenic purpura (itp) platelet count less than 75,000/mm3 on two occasions at least 1 week apart within past month normal to increased numbers of megakaryocytes on bone marrow examination within past 6 months failed prior steroid therapy (i.e., unable to achieve sustained platelet count greater than 75,000/mm3) no drug associated itp no b cell malignancies no evidence of disseminated intravascular coagulation (dic) --prior/concurrent therapy-- endocrine therapy: concurrent steroids allowed as long as platelet count is less than 75,000/mm3 and dose is not changed within past 2 weeks or during study other: * no other concurrent medical therapy for immune thrombocytopenia purpura (itp) * at least 2 weeks since prior therapy for itp (except steroids) * at least 4 weeks since prior cyclosporine --patient characteristics-- performance status: ecog 0-2 life expectancy: at least 6 months renal: creatinine no greater than 2.0 mg/dl cardiovascular: no congestive heart failure or symptomatic coronary insufficiency other: * no clinically significant bleeding (i.e., other than mild mucosal bleeding or petechiae) * no sepsis or fever * no active infection requiring therapy * no active chronic viral infection * hiv negative * no other concurrent or prior malignancy within past 5 years except squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception

Keywords: hematologic disorders immune thrombocytopenic purpura rare disease
feasibility of internet based support (carer esupport) for informal caregivers of patients with head and neck cancer

Conditions: Caregivers; Head and Neck Cancer; Feasibility Study

Summary: informal caregivers to patients with head and neck cancer report that they are unprepared for caregiving, that they experience a high caregiver burden and a deteriorated health. the aim is to develop an internet based intervention for informal caregivers of individuals with head and neck cancer and evaluate the feasibility and acceptability of the intervention. the internet based intervention (carer esupport) will be based on scientific evidence, established theoretical frameworks and focus groups with caregivers and health care professionals. the feasibility and acceptability of carer esupport will be evaluated by 30 caregivers who will have access to carer esupport during one months. the feasibility and acceptability of carer esupport will be evaluated with quantitative and qualitative data.


Eligibility criteria:
inclusion criteria: * informal caregivers (defined by the patients) to patients with head and neck cancer who are about to start treatment, undergoing treatment or have completed treatment within the past month. exclusion criteria: * confusion or dementia, inability to understand, speak or read swedish.
development of quality indicators and quality improvement plan of colonoscopy in experienced endoscopist

Conditions: Colonic Polyps; Colonic Neoplasms

Summary: the purpose of this study is to determine clinical factors affecting quality indicators of colonoscopy including adenoma detection rate, and whether quality of colonoscopy could be elevated by improving related factors.

this study is an extension of quality assurance program in seoul national university hospital healthcare system gangnam center. this study is composed of five periods. first, quality indicators of colonoscopy in experienced endoscopists will be analyzed retrospectively from january 2011 to december 2014. individual differences and changes of quality indicators in every endoscopist will be verified. in second period, from january 2015 to march 2015, quality assurance program will be activated. endoscopists will be educated by equip (endoscopic quality improvement program). also split-regimen bowel preparation instead of same-day regimen and boston bowel preparation scale will be introduced to standardize disparity of grading. third, prospective trial starts from april 2015 to march 2018. all endoscopists will receive feedbacks of their own adenoma detection rates in every 3 months. changes of quality indicators for each endoscopist will be investigated, and annually monitored by institutional review board. if there is a significant improvement of quality indicators in interim assessment, prospective trial will be extended until april 2018. fourth is wash-out period from april 2018 to march 2019. feedbacks will be stopped and adenoma detection rates and quality indicators of endoscopists will be compared with those from prospective period. finally, cumulative rate and mortality rate of colorectal cancers will be investigated until december 2019.

Eligibility criteria:
inclusion criteria: * customers who received colonoscopy in seoul national university hospital healthcare system gangnam center from 2011 to 2019. exclusion criteria: * age \<18 years * customers who refused to offer their health check up data * history of inflammatory bowel disease * history of familial adenomatous polyposis * customers who received incomplete colonoscopy * history of previous colorectal resection

Keywords: colonoscopy quality improvement adenoma detection rate
correlate brca1 protein expression with response to dna damaging chemotherapy

Conditions: Breast Cancer

Summary: primary objective: to evaluate if low brca1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with dna damaging chemotherapy agent, compared to historical controls secondary objective: to evaluate if low brca1 protein expression has a preferential effect on tumor progression when metastatic breast cancer patients are treated with dna damaging chemotherapy agent, compared to historical controls

dna is constantly subject to damage from exposures including drugs (including chemotherapy), sunlight and aging. certain genes in the human body help repair this damage (i.e. brca1 and other genes). the purpose of this study is to find out if brca1 protein expression has a role in response to chemotherapy drugs.

Eligibility criteria:
inclusion criteria: * metastatic breast cancer and have formalin-fixed, paraffin embedded primary tumor available for testing brca1 protein expression * adults over 18 years of age * have resolution of all acute toxic effects of any prior chemotherapy or radiotherapy to nci ctc grade ≤ 1 prior to study registration. * be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific screening procedures * be willing and able to comply with the treatment plan, scheduled clinic visits, laboratory and oncological tests and other study procedures * have a ecog performance status of 0 - 2 * measurable disease by ct by recist 1.1 to evaluate response * adequate bone marrow function defined as platelets 100 x 109 cells/l, neutrophils 1.5 x 109 cells/l, white blood cells (wbc) 3.0 x 109 cells/l and a hemoglobin 90 gm/l * creatinine \ 40 ml/min * liver function tests (ast and or alt) should be 2 x upper limit of normal (uln, defined as per laboratory where blood testing is done), total bilirubin 1.5 x uln (except for patients with liver metastases, alt and/or alt 5 times the upper limit of normal is accepted) exclusion criteria: * myocardial infarction within 6 months of registration * brain metastases unless documented to be controlled post completion of local therapy (surgery and/or radiation therapy) for at least four weeks prior to registration * pregnant or breast feeding women. women with child bearing potential must use effective measures to prevent pregnancy while receiving pegylated liposomal doxorubicin * have a concurrent active non-breast malignancy except for non-melanoma skin cancer * her2 positive tumors as defined by fda guidelines(3+ immunohistochemical staining, defined as uniform, intense membrane staining of more than 10% of invasive tumor cells, and for cases with 2+ staining showing gene amplification by fish, expressed as a ratio of more than 2 when comparing her-2 gene and chromosome 17 fluorescent signals)
magseed magnetic marker in locating axillary lymph nodes in patients with breast cancer undergoing surgery

Conditions: Breast Carcinoma Metastatic in Lymph Node; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7

Summary: this phase iv trial studies the side effects of the magseed magnetic marker and how well it works in locating lymph nodes in the underarm area in patients with breast cancer undergoing surgery. injecting a small metallic marker in or near the lymph node prior to surgery may help the surgeon locate the lymph nodes during surgery without using radiation.

primary objective: i. to provide evidence that the clipped lymph node and magseed can be successfully retrieved in the excised surgical specimen when magseed and sentimag are used for targeted axillary dissection in breast cancer patients. outline: patients receive the magseed marker via ultrasound guided injection into the previously clipped lymph node or within perinodal tissue =\< 3 mm from the clipped node. patients then undergo axillary lymph node localization and targeted dissection within 30 days. after completion of study, patients are followed up within 6-22 days post-surgery.

Eligibility criteria:
inclusion criteria: * histologically confirmed ct0-4, n1 breast cancer * axillary lymph node metastasis with pathologic confirmation by needle biopsy * clip placed in the sampled axillary lymph node before completing chemotherapy * received neoadjuvant chemotherapy prior to surgical resection * scheduled for targeted axillary dissection (defined as selective localization and removal of the clipped node and sentinel lymph node dissection \[slnd\]) * eastern cooperative oncology group (ecog) performance status 0-2 exclusion criteria: * distant metastases * inflammatory breast cancer * prior surgical axillary procedure including slnd or axillary node excision * prior history of breast cancer in the ipsilateral breast * history of lymphoma * the subject is known to be pregnant. premenopausal patients under the age of 50 must have a pregnancy test performed as standard of care before the magseed is placed * previous radiation to the breast or axilla * pacemaker of other implantable device in the chest wall
hypovitaminosis d and an inadequate pth response in chronic liver disease patients

Conditions: Chronic Liver Disease; Hypovitaminosis

Summary: the purpose of this study is to determine how common low levels of magnesium are in patients with end stage liver disease. in addition, investigator is trying to determine if low levels of magnesium affect the release of parathyroid hormone in patients with end stage liver disease and low vitamin d levels

hypovitaminosis d is a common condition found in patients referred for orthotopic liver transplant. the classical physiologic response to vitamin d deficiency is the development of secondary hyperparathyroidism. however, several previous studies have found a high incidence of inappropriate functional hypoparathyroidism in patients with chronic liver disease and hypovitaminosis d. the mechanism underlying this functional hypoparathyroidism is not understood but previous investigators have postulated that it is related to intracellular magnesium (mg) deficiency. our short term goals of this pilot project are two fold: (a) we will estimate the prevalence of magnesium deficiency in chronic liver disease patients by performing standard mg loading testing (b) we will examine the effects of acute intravenous mg infusion on the calcium-pth axis. the vitamin d-pth endocrine system is one of the principal regulators of calcium homeostasis and bone metabolism. metabolic bone disease is a quite pervasive problem in chronic liver disease patients. insight into this important endocrine system will aid us in our long term goals of addressing metabolic bone disease issues in this patient population.

Eligibility criteria:
inclusion criteria: chronic liver disease patients \> 18 years of age diagnosed end stage liver disease \>18 years of age presence of hypovitaminosis d glomerular filtration rate of 60 ml/min./1.73m2 or greater exclusion criteria: subjects with known parathyroid disease subjects taking magnesium supplementation \<18 years of age history of parathyroid disease current supplementation of magnesium abnormal baseline ekg current diagnosis of cancer or undergoing cancer treatment

Keywords: hypovitaminosis chronic liver disease